nodes	percent_of_prediction	percent_of_DWPC	metapath
Boceprevir—CYP3A5—Ifosfamide—testicular cancer	0.0997	0.231	CbGbCtD
Boceprevir—ABCB1—Dactinomycin—testicular cancer	0.0549	0.127	CbGbCtD
Boceprevir—CYP3A5—Etoposide—testicular cancer	0.0476	0.11	CbGbCtD
Boceprevir—CYP3A4—Ifosfamide—testicular cancer	0.0389	0.0901	CbGbCtD
Boceprevir—ABCB1—Vinblastine—testicular cancer	0.0344	0.0797	CbGbCtD
Boceprevir—ABCB1—Cisplatin—testicular cancer	0.0316	0.0731	CbGbCtD
Boceprevir—ABCB1—Etoposide—testicular cancer	0.031	0.0718	CbGbCtD
Boceprevir—ABCB1—Doxorubicin—testicular cancer	0.0211	0.049	CbGbCtD
Boceprevir—CYP3A4—Vinblastine—testicular cancer	0.0206	0.0478	CbGbCtD
Boceprevir—ABCB1—Methotrexate—testicular cancer	0.0205	0.0475	CbGbCtD
Boceprevir—CYP3A4—Etoposide—testicular cancer	0.0186	0.043	CbGbCtD
Boceprevir—CTSV—seminal vesicle—testicular cancer	0.0136	0.0872	CbGeAlD
Boceprevir—CYP3A4—Doxorubicin—testicular cancer	0.0127	0.0294	CbGbCtD
Boceprevir—CTSL—embryo—testicular cancer	0.0118	0.0758	CbGeAlD
Boceprevir—CTSL—seminal vesicle—testicular cancer	0.0111	0.0712	CbGeAlD
Boceprevir—CTSV—gonad—testicular cancer	0.00981	0.063	CbGeAlD
Boceprevir—CTSK—seminal vesicle—testicular cancer	0.00836	0.0536	CbGeAlD
Boceprevir—CTSL—gonad—testicular cancer	0.00801	0.0515	CbGeAlD
Boceprevir—CTSV—female gonad—testicular cancer	0.00797	0.0512	CbGeAlD
Boceprevir—CTSS—embryo—testicular cancer	0.00779	0.0501	CbGeAlD
Boceprevir—CTSS—seminal vesicle—testicular cancer	0.00732	0.047	CbGeAlD
Boceprevir—CTSV—testis—testicular cancer	0.00707	0.0454	CbGeAlD
Boceprevir—CTSL—female gonad—testicular cancer	0.00651	0.0418	CbGeAlD
Boceprevir—CTSK—gonad—testicular cancer	0.00604	0.0388	CbGeAlD
Boceprevir—CTSL—testis—testicular cancer	0.00578	0.0371	CbGeAlD
Boceprevir—CTSS—gonad—testicular cancer	0.00529	0.034	CbGeAlD
Boceprevir—CTSK—female gonad—testicular cancer	0.00491	0.0315	CbGeAlD
Boceprevir—CMA1—lymph node—testicular cancer	0.0049	0.0314	CbGeAlD
Boceprevir—CTSK—testis—testicular cancer	0.00435	0.0279	CbGeAlD
Boceprevir—CTSS—female gonad—testicular cancer	0.0043	0.0276	CbGeAlD
Boceprevir—CTSL—lymph node—testicular cancer	0.00419	0.0269	CbGeAlD
Boceprevir—CTSS—testis—testicular cancer	0.00381	0.0245	CbGeAlD
Boceprevir—CTSK—lymph node—testicular cancer	0.00315	0.0203	CbGeAlD
Boceprevir—CTSV—Activation of Matrix Metalloproteinases—MMP2—testicular cancer	0.00281	0.0627	CbGpPWpGaD
Boceprevir—CTSS—lymph node—testicular cancer	0.00276	0.0177	CbGeAlD
Boceprevir—CMA1—Activation of Matrix Metalloproteinases—MMP2—testicular cancer	0.00261	0.0583	CbGpPWpGaD
Boceprevir—CTSL—Collagen degradation—MMP2—testicular cancer	0.00245	0.0546	CbGpPWpGaD
Boceprevir—CTSK—Activation of Matrix Metalloproteinases—MMP2—testicular cancer	0.00232	0.0519	CbGpPWpGaD
Boceprevir—CTSK—Collagen degradation—MMP2—testicular cancer	0.00203	0.0453	CbGpPWpGaD
Boceprevir—CTSV—Endochondral Ossification—FGFR3—testicular cancer	0.00198	0.0442	CbGpPWpGaD
Boceprevir—CYP3A5—female gonad—testicular cancer	0.00143	0.00917	CbGeAlD
Boceprevir—ABCB1—embryo—testicular cancer	0.00138	0.00883	CbGeAlD
Boceprevir—CMA1—Signaling by SCF-KIT—KITLG—testicular cancer	0.00132	0.0294	CbGpPWpGaD
Boceprevir—ABCB1—seminal vesicle—testicular cancer	0.00129	0.00829	CbGeAlD
Boceprevir—CTSV—Degradation of the extracellular matrix—MMP2—testicular cancer	0.00124	0.0276	CbGpPWpGaD
Boceprevir—CTSL—Degradation of the extracellular matrix—MMP2—testicular cancer	0.00124	0.0276	CbGpPWpGaD
Boceprevir—CMA1—Degradation of the extracellular matrix—MMP2—testicular cancer	0.00115	0.0257	CbGpPWpGaD
Boceprevir—CTSK—Degradation of the extracellular matrix—MMP2—testicular cancer	0.00103	0.0229	CbGpPWpGaD
Boceprevir—CMA1—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000979	0.0219	CbGpPWpGaD
Boceprevir—ABCB1—gonad—testicular cancer	0.000933	0.00599	CbGeAlD
Boceprevir—CMA1—Signaling by SCF-KIT—KIT—testicular cancer	0.000899	0.0201	CbGpPWpGaD
Boceprevir—CTSS—Degradation of the extracellular matrix—MMP2—testicular cancer	0.000845	0.0189	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—BCL10—testicular cancer	0.000761	0.017	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—BCL10—testicular cancer	0.000761	0.017	CbGpPWpGaD
Boceprevir—ABCB1—female gonad—testicular cancer	0.000759	0.00487	CbGeAlD
Boceprevir—CTSV—Adaptive Immune System—BCL10—testicular cancer	0.000731	0.0163	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—BCL10—testicular cancer	0.000731	0.0163	CbGpPWpGaD
Boceprevir—ABCB1—testis—testicular cancer	0.000673	0.00432	CbGeAlD
Boceprevir—CTSK—Innate Immune System—BCL10—testicular cancer	0.000631	0.0141	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—BCL10—testicular cancer	0.000605	0.0135	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—INSL3—testicular cancer	0.000546	0.0122	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—BCL10—testicular cancer	0.000519	0.0116	CbGpPWpGaD
Boceprevir—CTSV—Extracellular matrix organization—MMP2—testicular cancer	0.000519	0.0116	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—MMP2—testicular cancer	0.000519	0.0116	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—BCL10—testicular cancer	0.000499	0.0111	CbGpPWpGaD
Boceprevir—ABCB1—lymph node—testicular cancer	0.000488	0.00313	CbGeAlD
Boceprevir—CMA1—Extracellular matrix organization—MMP2—testicular cancer	0.000482	0.0108	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—KITLG—testicular cancer	0.000459	0.0103	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—KITLG—testicular cancer	0.000459	0.0103	CbGpPWpGaD
Boceprevir—CTSV—Immune System—BCL10—testicular cancer	0.000443	0.0099	CbGpPWpGaD
Boceprevir—CTSL—Immune System—BCL10—testicular cancer	0.000443	0.0099	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—KITLG—testicular cancer	0.000441	0.00984	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—KITLG—testicular cancer	0.000441	0.00984	CbGpPWpGaD
Boceprevir—CTSK—Extracellular matrix organization—MMP2—testicular cancer	0.00043	0.0096	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—KITLG—testicular cancer	0.00038	0.00849	CbGpPWpGaD
Boceprevir—CTSK—Immune System—BCL10—testicular cancer	0.000367	0.0082	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—KITLG—testicular cancer	0.000365	0.00816	CbGpPWpGaD
Boceprevir—CTSS—Extracellular matrix organization—MMP2—testicular cancer	0.000354	0.00791	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—FGFR3—testicular cancer	0.000341	0.00762	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—FGFR3—testicular cancer	0.000341	0.00762	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—FGFR3—testicular cancer	0.000327	0.00732	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—FGFR3—testicular cancer	0.000327	0.00732	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—KIT—testicular cancer	0.000313	0.00699	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—KIT—testicular cancer	0.000313	0.00699	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—KITLG—testicular cancer	0.000313	0.00699	CbGpPWpGaD
Boceprevir—CTSS—Immune System—BCL10—testicular cancer	0.000302	0.00676	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—KITLG—testicular cancer	0.000301	0.00672	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—KIT—testicular cancer	0.000301	0.00672	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—KIT—testicular cancer	0.000301	0.00672	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—FGFR3—testicular cancer	0.000283	0.00631	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—FGFR3—testicular cancer	0.000271	0.00606	CbGpPWpGaD
Boceprevir—CYP3A5—Biological oxidations—HPGDS—testicular cancer	0.000268	0.00598	CbGpPWpGaD
Boceprevir—CTSV—Immune System—KITLG—testicular cancer	0.000267	0.00597	CbGpPWpGaD
Boceprevir—CTSL—Immune System—KITLG—testicular cancer	0.000267	0.00597	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—KIT—testicular cancer	0.000259	0.0058	CbGpPWpGaD
Boceprevir—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000253	0.00566	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—KIT—testicular cancer	0.000249	0.00557	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—FGFR3—testicular cancer	0.000233	0.0052	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—MMP2—testicular cancer	0.000225	0.00503	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—FGFR3—testicular cancer	0.000223	0.00499	CbGpPWpGaD
Boceprevir—CTSK—Immune System—KITLG—testicular cancer	0.000221	0.00495	CbGpPWpGaD
Boceprevir—Infestation—Doxorubicin—testicular cancer	0.000215	0.000583	CcSEcCtD
Boceprevir—Visual impairment—Methotrexate—testicular cancer	0.000214	0.000582	CcSEcCtD
Boceprevir—CTSS—Innate Immune System—KIT—testicular cancer	0.000214	0.00477	CbGpPWpGaD
Boceprevir—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000213	0.000578	CcSEcCtD
Boceprevir—Vomiting—Ifosfamide—testicular cancer	0.000212	0.000577	CcSEcCtD
Boceprevir—Hypersensitivity—Cisplatin—testicular cancer	0.000212	0.000576	CcSEcCtD
Boceprevir—Rash—Ifosfamide—testicular cancer	0.000211	0.000572	CcSEcCtD
Boceprevir—Dermatitis—Ifosfamide—testicular cancer	0.00021	0.000572	CcSEcCtD
Boceprevir—Erythema multiforme—Methotrexate—testicular cancer	0.00021	0.000571	CcSEcCtD
Boceprevir—Neuropathy peripheral—Doxorubicin—testicular cancer	0.00021	0.000571	CcSEcCtD
Boceprevir—Urticaria—Etoposide—testicular cancer	0.00021	0.000569	CcSEcCtD
Boceprevir—Stomatitis—Doxorubicin—testicular cancer	0.000209	0.000568	CcSEcCtD
Boceprevir—Rhinitis—Epirubicin—testicular cancer	0.000209	0.000567	CcSEcCtD
Boceprevir—Body temperature increased—Etoposide—testicular cancer	0.000209	0.000567	CcSEcCtD
Boceprevir—Abdominal pain—Etoposide—testicular cancer	0.000209	0.000567	CcSEcCtD
Boceprevir—Conjunctivitis—Doxorubicin—testicular cancer	0.000209	0.000567	CcSEcCtD
Boceprevir—Urinary tract infection—Doxorubicin—testicular cancer	0.000209	0.000567	CcSEcCtD
Boceprevir—Eye disorder—Methotrexate—testicular cancer	0.000208	0.000565	CcSEcCtD
Boceprevir—Tinnitus—Methotrexate—testicular cancer	0.000207	0.000563	CcSEcCtD
Boceprevir—Hypoaesthesia—Epirubicin—testicular cancer	0.000207	0.000563	CcSEcCtD
Boceprevir—Asthenia—Cisplatin—testicular cancer	0.000207	0.000561	CcSEcCtD
Boceprevir—Pharyngitis—Epirubicin—testicular cancer	0.000207	0.000561	CcSEcCtD
Boceprevir—Cardiac disorder—Methotrexate—testicular cancer	0.000206	0.000561	CcSEcCtD
Boceprevir—Urinary tract disorder—Epirubicin—testicular cancer	0.000206	0.000558	CcSEcCtD
Boceprevir—CTSS—Adaptive Immune System—KIT—testicular cancer	0.000205	0.00458	CbGpPWpGaD
Boceprevir—Oedema peripheral—Epirubicin—testicular cancer	0.000205	0.000557	CcSEcCtD
Boceprevir—Connective tissue disorder—Epirubicin—testicular cancer	0.000205	0.000556	CcSEcCtD
Boceprevir—Urethral disorder—Epirubicin—testicular cancer	0.000204	0.000554	CcSEcCtD
Boceprevir—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000203	0.00454	CbGpPWpGaD
Boceprevir—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000203	0.000551	CcSEcCtD
Boceprevir—Epistaxis—Doxorubicin—testicular cancer	0.000202	0.00055	CcSEcCtD
Boceprevir—Angiopathy—Methotrexate—testicular cancer	0.000202	0.000548	CcSEcCtD
Boceprevir—Sinusitis—Doxorubicin—testicular cancer	0.000201	0.000547	CcSEcCtD
Boceprevir—Immune system disorder—Methotrexate—testicular cancer	0.000201	0.000546	CcSEcCtD
Boceprevir—Visual impairment—Epirubicin—testicular cancer	0.000201	0.000545	CcSEcCtD
Boceprevir—Mediastinal disorder—Methotrexate—testicular cancer	0.0002	0.000545	CcSEcCtD
Boceprevir—Agranulocytosis—Doxorubicin—testicular cancer	0.0002	0.000544	CcSEcCtD
Boceprevir—Chills—Methotrexate—testicular cancer	0.0002	0.000542	CcSEcCtD
Boceprevir—CTSL—Immune System—FGFR3—testicular cancer	0.000199	0.00444	CbGpPWpGaD
Boceprevir—CTSV—Immune System—FGFR3—testicular cancer	0.000199	0.00444	CbGpPWpGaD
Boceprevir—Nausea—Ifosfamide—testicular cancer	0.000198	0.000539	CcSEcCtD
Boceprevir—Diarrhoea—Cisplatin—testicular cancer	0.000197	0.000535	CcSEcCtD
Boceprevir—Erythema multiforme—Epirubicin—testicular cancer	0.000197	0.000535	CcSEcCtD
Boceprevir—Alopecia—Methotrexate—testicular cancer	0.000197	0.000534	CcSEcCtD
Boceprevir—Mental disorder—Methotrexate—testicular cancer	0.000195	0.000529	CcSEcCtD
Boceprevir—Eye disorder—Epirubicin—testicular cancer	0.000194	0.000529	CcSEcCtD
Boceprevir—Hypersensitivity—Etoposide—testicular cancer	0.000194	0.000528	CcSEcCtD
Boceprevir—Tinnitus—Epirubicin—testicular cancer	0.000194	0.000527	CcSEcCtD
Boceprevir—Erythema—Methotrexate—testicular cancer	0.000194	0.000526	CcSEcCtD
Boceprevir—Malnutrition—Methotrexate—testicular cancer	0.000194	0.000526	CcSEcCtD
Boceprevir—Cardiac disorder—Epirubicin—testicular cancer	0.000193	0.000525	CcSEcCtD
Boceprevir—Flushing—Epirubicin—testicular cancer	0.000193	0.000525	CcSEcCtD
Boceprevir—Rhinitis—Doxorubicin—testicular cancer	0.000193	0.000525	CcSEcCtD
Boceprevir—Hypoaesthesia—Doxorubicin—testicular cancer	0.000192	0.000521	CcSEcCtD
Boceprevir—Pharyngitis—Doxorubicin—testicular cancer	0.000191	0.000519	CcSEcCtD
Boceprevir—Urinary tract disorder—Doxorubicin—testicular cancer	0.00019	0.000517	CcSEcCtD
Boceprevir—Oedema peripheral—Doxorubicin—testicular cancer	0.00019	0.000515	CcSEcCtD
Boceprevir—Dysgeusia—Methotrexate—testicular cancer	0.00019	0.000515	CcSEcCtD
Boceprevir—Asthenia—Etoposide—testicular cancer	0.000189	0.000514	CcSEcCtD
Boceprevir—Connective tissue disorder—Doxorubicin—testicular cancer	0.000189	0.000514	CcSEcCtD
Boceprevir—Angiopathy—Epirubicin—testicular cancer	0.000189	0.000513	CcSEcCtD
Boceprevir—Urethral disorder—Doxorubicin—testicular cancer	0.000189	0.000513	CcSEcCtD
Boceprevir—Immune system disorder—Epirubicin—testicular cancer	0.000188	0.000511	CcSEcCtD
Boceprevir—Mediastinal disorder—Epirubicin—testicular cancer	0.000188	0.00051	CcSEcCtD
Boceprevir—Back pain—Methotrexate—testicular cancer	0.000187	0.000509	CcSEcCtD
Boceprevir—Chills—Epirubicin—testicular cancer	0.000187	0.000507	CcSEcCtD
Boceprevir—Pruritus—Etoposide—testicular cancer	0.000187	0.000507	CcSEcCtD
Boceprevir—Arrhythmia—Epirubicin—testicular cancer	0.000186	0.000505	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000186	0.00415	CbGpPWpGaD
Boceprevir—Visual impairment—Doxorubicin—testicular cancer	0.000186	0.000504	CcSEcCtD
Boceprevir—Alopecia—Epirubicin—testicular cancer	0.000184	0.0005	CcSEcCtD
Boceprevir—Vomiting—Cisplatin—testicular cancer	0.000183	0.000497	CcSEcCtD
Boceprevir—Vision blurred—Methotrexate—testicular cancer	0.000182	0.000496	CcSEcCtD
Boceprevir—CTSS—Immune System—KITLG—testicular cancer	0.000182	0.00407	CbGpPWpGaD
Boceprevir—CTSV—Immune System—KIT—testicular cancer	0.000182	0.00407	CbGpPWpGaD
Boceprevir—CTSL—Immune System—KIT—testicular cancer	0.000182	0.00407	CbGpPWpGaD
Boceprevir—Mental disorder—Epirubicin—testicular cancer	0.000182	0.000495	CcSEcCtD
Boceprevir—Erythema multiforme—Doxorubicin—testicular cancer	0.000182	0.000495	CcSEcCtD
Boceprevir—Rash—Cisplatin—testicular cancer	0.000182	0.000493	CcSEcCtD
Boceprevir—Dermatitis—Cisplatin—testicular cancer	0.000181	0.000493	CcSEcCtD
Boceprevir—Malnutrition—Epirubicin—testicular cancer	0.000181	0.000492	CcSEcCtD
Boceprevir—Erythema—Epirubicin—testicular cancer	0.000181	0.000492	CcSEcCtD
Boceprevir—Diarrhoea—Etoposide—testicular cancer	0.00018	0.00049	CcSEcCtD
Boceprevir—Eye disorder—Doxorubicin—testicular cancer	0.00018	0.000489	CcSEcCtD
Boceprevir—Ill-defined disorder—Methotrexate—testicular cancer	0.00018	0.000488	CcSEcCtD
Boceprevir—Tinnitus—Doxorubicin—testicular cancer	0.00018	0.000488	CcSEcCtD
Boceprevir—Anaemia—Methotrexate—testicular cancer	0.000179	0.000486	CcSEcCtD
Boceprevir—Cardiac disorder—Doxorubicin—testicular cancer	0.000179	0.000486	CcSEcCtD
Boceprevir—Flushing—Doxorubicin—testicular cancer	0.000179	0.000486	CcSEcCtD
Boceprevir—Flatulence—Epirubicin—testicular cancer	0.000179	0.000485	CcSEcCtD
Boceprevir—Dysgeusia—Epirubicin—testicular cancer	0.000177	0.000482	CcSEcCtD
Boceprevir—Back pain—Epirubicin—testicular cancer	0.000175	0.000476	CcSEcCtD
Boceprevir—Angiopathy—Doxorubicin—testicular cancer	0.000175	0.000475	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—H2AFZ—testicular cancer	0.000175	0.0039	CbGpPWpGaD
Boceprevir—Malaise—Methotrexate—testicular cancer	0.000175	0.000474	CcSEcCtD
Boceprevir—Dizziness—Etoposide—testicular cancer	0.000174	0.000474	CcSEcCtD
Boceprevir—Muscle spasms—Epirubicin—testicular cancer	0.000174	0.000473	CcSEcCtD
Boceprevir—Immune system disorder—Doxorubicin—testicular cancer	0.000174	0.000473	CcSEcCtD
Boceprevir—Vertigo—Methotrexate—testicular cancer	0.000174	0.000473	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—STK11—testicular cancer	0.000174	0.00388	CbGpPWpGaD
Boceprevir—Mediastinal disorder—Doxorubicin—testicular cancer	0.000174	0.000472	CcSEcCtD
Boceprevir—Leukopenia—Methotrexate—testicular cancer	0.000173	0.000471	CcSEcCtD
Boceprevir—Chills—Doxorubicin—testicular cancer	0.000173	0.00047	CcSEcCtD
Boceprevir—Arrhythmia—Doxorubicin—testicular cancer	0.000172	0.000467	CcSEcCtD
Boceprevir—Nausea—Cisplatin—testicular cancer	0.000171	0.000465	CcSEcCtD
Boceprevir—Vision blurred—Epirubicin—testicular cancer	0.000171	0.000464	CcSEcCtD
Boceprevir—Alopecia—Doxorubicin—testicular cancer	0.00017	0.000462	CcSEcCtD
Boceprevir—Cough—Methotrexate—testicular cancer	0.000169	0.000459	CcSEcCtD
Boceprevir—Mental disorder—Doxorubicin—testicular cancer	0.000169	0.000458	CcSEcCtD
Boceprevir—Ill-defined disorder—Epirubicin—testicular cancer	0.000168	0.000457	CcSEcCtD
Boceprevir—Vomiting—Etoposide—testicular cancer	0.000168	0.000456	CcSEcCtD
Boceprevir—Erythema—Doxorubicin—testicular cancer	0.000168	0.000456	CcSEcCtD
Boceprevir—Malnutrition—Doxorubicin—testicular cancer	0.000168	0.000456	CcSEcCtD
Boceprevir—Anaemia—Epirubicin—testicular cancer	0.000167	0.000455	CcSEcCtD
Boceprevir—Agitation—Epirubicin—testicular cancer	0.000166	0.000452	CcSEcCtD
Boceprevir—Rash—Etoposide—testicular cancer	0.000166	0.000452	CcSEcCtD
Boceprevir—Dermatitis—Etoposide—testicular cancer	0.000166	0.000452	CcSEcCtD
Boceprevir—Headache—Etoposide—testicular cancer	0.000165	0.000449	CcSEcCtD
Boceprevir—Flatulence—Doxorubicin—testicular cancer	0.000165	0.000449	CcSEcCtD
Boceprevir—Arthralgia—Methotrexate—testicular cancer	0.000165	0.000448	CcSEcCtD
Boceprevir—Myalgia—Methotrexate—testicular cancer	0.000165	0.000448	CcSEcCtD
Boceprevir—Chest pain—Methotrexate—testicular cancer	0.000165	0.000448	CcSEcCtD
Boceprevir—CTSK—Immune System—FGFR3—testicular cancer	0.000165	0.00368	CbGpPWpGaD
Boceprevir—Dysgeusia—Doxorubicin—testicular cancer	0.000164	0.000446	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000164	0.000445	CcSEcCtD
Boceprevir—Malaise—Epirubicin—testicular cancer	0.000163	0.000444	CcSEcCtD
Boceprevir—Discomfort—Methotrexate—testicular cancer	0.000163	0.000442	CcSEcCtD
Boceprevir—Vertigo—Epirubicin—testicular cancer	0.000163	0.000442	CcSEcCtD
Boceprevir—Syncope—Epirubicin—testicular cancer	0.000162	0.000441	CcSEcCtD
Boceprevir—Leukopenia—Epirubicin—testicular cancer	0.000162	0.000441	CcSEcCtD
Boceprevir—Back pain—Doxorubicin—testicular cancer	0.000162	0.000441	CcSEcCtD
Boceprevir—Muscle spasms—Doxorubicin—testicular cancer	0.000161	0.000438	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—KITLG—testicular cancer	0.000161	0.00359	CbGpPWpGaD
Boceprevir—Palpitations—Epirubicin—testicular cancer	0.00016	0.000435	CcSEcCtD
Boceprevir—Confusional state—Methotrexate—testicular cancer	0.000159	0.000433	CcSEcCtD
Boceprevir—Loss of consciousness—Epirubicin—testicular cancer	0.000159	0.000433	CcSEcCtD
Boceprevir—Cough—Epirubicin—testicular cancer	0.000158	0.00043	CcSEcCtD
Boceprevir—Vision blurred—Doxorubicin—testicular cancer	0.000158	0.000429	CcSEcCtD
Boceprevir—Infection—Methotrexate—testicular cancer	0.000157	0.000427	CcSEcCtD
Boceprevir—Nausea—Etoposide—testicular cancer	0.000157	0.000426	CcSEcCtD
Boceprevir—Hypertension—Epirubicin—testicular cancer	0.000156	0.000425	CcSEcCtD
Boceprevir—Ill-defined disorder—Doxorubicin—testicular cancer	0.000156	0.000423	CcSEcCtD
Boceprevir—Nervous system disorder—Methotrexate—testicular cancer	0.000155	0.000421	CcSEcCtD
Boceprevir—Anaemia—Doxorubicin—testicular cancer	0.000155	0.000421	CcSEcCtD
Boceprevir—Thrombocytopenia—Methotrexate—testicular cancer	0.000155	0.00042	CcSEcCtD
Boceprevir—Myalgia—Epirubicin—testicular cancer	0.000154	0.000419	CcSEcCtD
Boceprevir—Arthralgia—Epirubicin—testicular cancer	0.000154	0.000419	CcSEcCtD
Boceprevir—Chest pain—Epirubicin—testicular cancer	0.000154	0.000419	CcSEcCtD
Boceprevir—Agitation—Doxorubicin—testicular cancer	0.000154	0.000419	CcSEcCtD
Boceprevir—Anxiety—Epirubicin—testicular cancer	0.000154	0.000418	CcSEcCtD
Boceprevir—Skin disorder—Methotrexate—testicular cancer	0.000153	0.000417	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000153	0.000416	CcSEcCtD
Boceprevir—Hyperhidrosis—Methotrexate—testicular cancer	0.000153	0.000415	CcSEcCtD
Boceprevir—Discomfort—Epirubicin—testicular cancer	0.000152	0.000414	CcSEcCtD
Boceprevir—Malaise—Doxorubicin—testicular cancer	0.000151	0.000411	CcSEcCtD
Boceprevir—CTSK—Immune System—KIT—testicular cancer	0.000151	0.00338	CbGpPWpGaD
Boceprevir—Dry mouth—Epirubicin—testicular cancer	0.000151	0.00041	CcSEcCtD
Boceprevir—Vertigo—Doxorubicin—testicular cancer	0.000151	0.000409	CcSEcCtD
Boceprevir—Syncope—Doxorubicin—testicular cancer	0.00015	0.000408	CcSEcCtD
Boceprevir—Leukopenia—Doxorubicin—testicular cancer	0.00015	0.000408	CcSEcCtD
Boceprevir—Confusional state—Epirubicin—testicular cancer	0.000149	0.000405	CcSEcCtD
Boceprevir—Palpitations—Doxorubicin—testicular cancer	0.000148	0.000403	CcSEcCtD
Boceprevir—Hypotension—Methotrexate—testicular cancer	0.000148	0.000401	CcSEcCtD
Boceprevir—Loss of consciousness—Doxorubicin—testicular cancer	0.000147	0.0004	CcSEcCtD
Boceprevir—Infection—Epirubicin—testicular cancer	0.000147	0.000399	CcSEcCtD
Boceprevir—Cough—Doxorubicin—testicular cancer	0.000146	0.000397	CcSEcCtD
Boceprevir—Shock—Epirubicin—testicular cancer	0.000145	0.000395	CcSEcCtD
Boceprevir—Nervous system disorder—Epirubicin—testicular cancer	0.000145	0.000394	CcSEcCtD
Boceprevir—Thrombocytopenia—Epirubicin—testicular cancer	0.000145	0.000393	CcSEcCtD
Boceprevir—Hypertension—Doxorubicin—testicular cancer	0.000145	0.000393	CcSEcCtD
Boceprevir—Tachycardia—Epirubicin—testicular cancer	0.000144	0.000392	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000144	0.000391	CcSEcCtD
Boceprevir—Skin disorder—Epirubicin—testicular cancer	0.000144	0.00039	CcSEcCtD
Boceprevir—Hyperhidrosis—Epirubicin—testicular cancer	0.000143	0.000388	CcSEcCtD
Boceprevir—Insomnia—Methotrexate—testicular cancer	0.000143	0.000388	CcSEcCtD
Boceprevir—Chest pain—Doxorubicin—testicular cancer	0.000143	0.000388	CcSEcCtD
Boceprevir—Myalgia—Doxorubicin—testicular cancer	0.000143	0.000388	CcSEcCtD
Boceprevir—Arthralgia—Doxorubicin—testicular cancer	0.000143	0.000388	CcSEcCtD
Boceprevir—Anxiety—Doxorubicin—testicular cancer	0.000142	0.000386	CcSEcCtD
Boceprevir—Paraesthesia—Methotrexate—testicular cancer	0.000142	0.000386	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000142	0.000385	CcSEcCtD
Boceprevir—Discomfort—Doxorubicin—testicular cancer	0.000141	0.000383	CcSEcCtD
Boceprevir—Dyspnoea—Methotrexate—testicular cancer	0.000141	0.000383	CcSEcCtD
Boceprevir—Dry mouth—Doxorubicin—testicular cancer	0.00014	0.000379	CcSEcCtD
Boceprevir—Dyspepsia—Methotrexate—testicular cancer	0.000139	0.000378	CcSEcCtD
Boceprevir—Hypotension—Epirubicin—testicular cancer	0.000138	0.000375	CcSEcCtD
Boceprevir—Confusional state—Doxorubicin—testicular cancer	0.000138	0.000375	CcSEcCtD
Boceprevir—Decreased appetite—Methotrexate—testicular cancer	0.000137	0.000373	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000136	0.000371	CcSEcCtD
Boceprevir—Fatigue—Methotrexate—testicular cancer	0.000136	0.00037	CcSEcCtD
Boceprevir—Infection—Doxorubicin—testicular cancer	0.000136	0.000369	CcSEcCtD
Boceprevir—CTSS—Immune System—FGFR3—testicular cancer	0.000136	0.00303	CbGpPWpGaD
Boceprevir—Pain—Methotrexate—testicular cancer	0.000135	0.000367	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000135	0.00302	CbGpPWpGaD
Boceprevir—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000135	0.000366	CcSEcCtD
Boceprevir—Shock—Doxorubicin—testicular cancer	0.000135	0.000366	CcSEcCtD
Boceprevir—Nervous system disorder—Doxorubicin—testicular cancer	0.000134	0.000365	CcSEcCtD
Boceprevir—Thrombocytopenia—Doxorubicin—testicular cancer	0.000134	0.000364	CcSEcCtD
Boceprevir—Insomnia—Epirubicin—testicular cancer	0.000134	0.000363	CcSEcCtD
Boceprevir—Tachycardia—Doxorubicin—testicular cancer	0.000134	0.000363	CcSEcCtD
Boceprevir—Skin disorder—Doxorubicin—testicular cancer	0.000133	0.000361	CcSEcCtD
Boceprevir—Paraesthesia—Epirubicin—testicular cancer	0.000133	0.000361	CcSEcCtD
Boceprevir—Hyperhidrosis—Doxorubicin—testicular cancer	0.000132	0.000359	CcSEcCtD
Boceprevir—Dyspnoea—Epirubicin—testicular cancer	0.000132	0.000358	CcSEcCtD
Boceprevir—Feeling abnormal—Methotrexate—testicular cancer	0.00013	0.000354	CcSEcCtD
Boceprevir—Dyspepsia—Epirubicin—testicular cancer	0.00013	0.000354	CcSEcCtD
Boceprevir—Gastrointestinal pain—Methotrexate—testicular cancer	0.000129	0.000351	CcSEcCtD
Boceprevir—Decreased appetite—Epirubicin—testicular cancer	0.000129	0.000349	CcSEcCtD
Boceprevir—Hypotension—Doxorubicin—testicular cancer	0.000128	0.000347	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000128	0.000347	CcSEcCtD
Boceprevir—Fatigue—Epirubicin—testicular cancer	0.000127	0.000346	CcSEcCtD
Boceprevir—Pain—Epirubicin—testicular cancer	0.000126	0.000344	CcSEcCtD
Boceprevir—Constipation—Epirubicin—testicular cancer	0.000126	0.000344	CcSEcCtD
Boceprevir—Urticaria—Methotrexate—testicular cancer	0.000126	0.000341	CcSEcCtD
Boceprevir—Abdominal pain—Methotrexate—testicular cancer	0.000125	0.000339	CcSEcCtD
Boceprevir—Body temperature increased—Methotrexate—testicular cancer	0.000125	0.000339	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000125	0.000339	CcSEcCtD
Boceprevir—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000125	0.00278	CbGpPWpGaD
Boceprevir—CTSS—Immune System—KIT—testicular cancer	0.000124	0.00278	CbGpPWpGaD
Boceprevir—Insomnia—Doxorubicin—testicular cancer	0.000124	0.000336	CcSEcCtD
Boceprevir—Paraesthesia—Doxorubicin—testicular cancer	0.000123	0.000334	CcSEcCtD
Boceprevir—Dyspnoea—Doxorubicin—testicular cancer	0.000122	0.000331	CcSEcCtD
Boceprevir—Feeling abnormal—Epirubicin—testicular cancer	0.000122	0.000331	CcSEcCtD
Boceprevir—Gastrointestinal pain—Epirubicin—testicular cancer	0.000121	0.000329	CcSEcCtD
Boceprevir—Dyspepsia—Doxorubicin—testicular cancer	0.00012	0.000327	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—FGFR3—testicular cancer	0.000119	0.00267	CbGpPWpGaD
Boceprevir—Decreased appetite—Doxorubicin—testicular cancer	0.000119	0.000323	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000118	0.000321	CcSEcCtD
Boceprevir—Fatigue—Doxorubicin—testicular cancer	0.000118	0.000321	CcSEcCtD
Boceprevir—Urticaria—Epirubicin—testicular cancer	0.000117	0.000319	CcSEcCtD
Boceprevir—Pain—Doxorubicin—testicular cancer	0.000117	0.000318	CcSEcCtD
Boceprevir—Constipation—Doxorubicin—testicular cancer	0.000117	0.000318	CcSEcCtD
Boceprevir—Abdominal pain—Epirubicin—testicular cancer	0.000117	0.000318	CcSEcCtD
Boceprevir—Body temperature increased—Epirubicin—testicular cancer	0.000117	0.000318	CcSEcCtD
Boceprevir—Hypersensitivity—Methotrexate—testicular cancer	0.000116	0.000316	CcSEcCtD
Boceprevir—Asthenia—Methotrexate—testicular cancer	0.000113	0.000308	CcSEcCtD
Boceprevir—Feeling abnormal—Doxorubicin—testicular cancer	0.000113	0.000306	CcSEcCtD
Boceprevir—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000112	0.000304	CcSEcCtD
Boceprevir—Pruritus—Methotrexate—testicular cancer	0.000112	0.000304	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—KIT—testicular cancer	0.00011	0.00245	CbGpPWpGaD
Boceprevir—Hypersensitivity—Epirubicin—testicular cancer	0.000109	0.000296	CcSEcCtD
Boceprevir—Urticaria—Doxorubicin—testicular cancer	0.000109	0.000295	CcSEcCtD
Boceprevir—Abdominal pain—Doxorubicin—testicular cancer	0.000108	0.000294	CcSEcCtD
Boceprevir—Body temperature increased—Doxorubicin—testicular cancer	0.000108	0.000294	CcSEcCtD
Boceprevir—Diarrhoea—Methotrexate—testicular cancer	0.000108	0.000294	CcSEcCtD
Boceprevir—Asthenia—Epirubicin—testicular cancer	0.000106	0.000288	CcSEcCtD
Boceprevir—Pruritus—Epirubicin—testicular cancer	0.000105	0.000284	CcSEcCtD
Boceprevir—Dizziness—Methotrexate—testicular cancer	0.000104	0.000284	CcSEcCtD
Boceprevir—Diarrhoea—Epirubicin—testicular cancer	0.000101	0.000275	CcSEcCtD
Boceprevir—Hypersensitivity—Doxorubicin—testicular cancer	0.000101	0.000274	CcSEcCtD
Boceprevir—Vomiting—Methotrexate—testicular cancer	0.0001	0.000273	CcSEcCtD
Boceprevir—Rash—Methotrexate—testicular cancer	9.96e-05	0.000271	CcSEcCtD
Boceprevir—Dermatitis—Methotrexate—testicular cancer	9.95e-05	0.00027	CcSEcCtD
Boceprevir—Headache—Methotrexate—testicular cancer	9.9e-05	0.000269	CcSEcCtD
Boceprevir—Asthenia—Doxorubicin—testicular cancer	9.82e-05	0.000267	CcSEcCtD
Boceprevir—Dizziness—Epirubicin—testicular cancer	9.78e-05	0.000266	CcSEcCtD
Boceprevir—Pruritus—Doxorubicin—testicular cancer	9.68e-05	0.000263	CcSEcCtD
Boceprevir—Vomiting—Epirubicin—testicular cancer	9.4e-05	0.000255	CcSEcCtD
Boceprevir—Nausea—Methotrexate—testicular cancer	9.39e-05	0.000255	CcSEcCtD
Boceprevir—Diarrhoea—Doxorubicin—testicular cancer	9.36e-05	0.000254	CcSEcCtD
Boceprevir—Rash—Epirubicin—testicular cancer	9.32e-05	0.000253	CcSEcCtD
Boceprevir—Dermatitis—Epirubicin—testicular cancer	9.31e-05	0.000253	CcSEcCtD
Boceprevir—Headache—Epirubicin—testicular cancer	9.26e-05	0.000252	CcSEcCtD
Boceprevir—Dizziness—Doxorubicin—testicular cancer	9.05e-05	0.000246	CcSEcCtD
Boceprevir—Nausea—Epirubicin—testicular cancer	8.78e-05	0.000239	CcSEcCtD
Boceprevir—Vomiting—Doxorubicin—testicular cancer	8.7e-05	0.000236	CcSEcCtD
Boceprevir—Rash—Doxorubicin—testicular cancer	8.63e-05	0.000234	CcSEcCtD
Boceprevir—Dermatitis—Doxorubicin—testicular cancer	8.62e-05	0.000234	CcSEcCtD
Boceprevir—Headache—Doxorubicin—testicular cancer	8.57e-05	0.000233	CcSEcCtD
Boceprevir—Nausea—Doxorubicin—testicular cancer	8.13e-05	0.000221	CcSEcCtD
Boceprevir—CYP3A5—Metabolism—HPGDS—testicular cancer	4.58e-05	0.00102	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—HPGDS—testicular cancer	3.46e-05	0.000772	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—STK11—testicular cancer	3.33e-05	0.000744	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—STK11—testicular cancer	2.51e-05	0.000561	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—HPGDS—testicular cancer	2.13e-05	0.000476	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—STK11—testicular cancer	1.55e-05	0.000346	CbGpPWpGaD
